TP53BP1 and neoplasm: These Polθ inhibitors not only target BRCA1/2 mutant tumour cells and enhance the synthetic lethal effects of PARPi, but also target PARPi resistant tumour cells with defects in the 53BP1/Shieldin [17, 18], described above.